FDA's biosimilar safety net quietly loosened—faster drugs, less proof

What it does

This bill amends the FDA's biosimilar approval process to make it easier and faster for generic versions of complex biologic drugs to reach the market. Specifically, it changes the default expectation so that companies seeking to license a biosimilar no longer automatically have to conduct expensive clinical studies measuring how the drug works in the body (pharmacodynamics) or comparing its real-world effectiveness to the original drug—they only need to show the drug behaves similarly at the molecular level and in limited clinical settings. The FDA can still require these studies if it determines they are necessary, but must notify the sponsor in writing and justify the decision.

Why we flagged it

The bill functionally reduces FDA's default evidentiary burden for biosimilar licensure by removing the presumptive requirement for pharmacodynamics and comparative efficacy studies. It is a deregulatory measure framed as 'expedited access,' shifting the burden from applicants to prove equivalence to the FDA to affirmatively justify why additional proof is needed.

What the text implies

• The bill shifts the burden of proof: instead of biosimilar sponsors having to demonstrate equivalence through clinical studies, the FDA must now affirmatively justify why such studies are necessary. This reversal may slow FDA decision-making if the agency lacks resources to conduct rapid written justifications within 60 days.
• Biosimilars approved under the new standard may enter the market with only molecular-level and limited clinical data, potentially missing real-world efficacy or safety signals that would emerge in broader patient populations—especially in immunocompromised or elderly patients not well-represented in minimal studies.

The full analysis lists 4 implications of this text.

Who stands to gain

biosimilar manufacturers; generic drug companies; pharmacy benefit managers